While large prospective clinical trials designed solely to link P-gp expression to overall MM outcomes independent of specific drug regimens are less common, numerous studies in patient cohorts treated with standard therapies provide clinical evidence suggesting P-gp’s involvement in resistance and its potential impact on prognosis depending on the specific drugs used [49]. The gene discussed is PGP; the disease is Miyoshi myopathy.